New combo therapy aims to stop leukemia from coming back after transplant
NCT ID NCT04187105
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding a precise, targeted form of radiation to the standard chemotherapy and stem cell transplant can kill more cancer cells in the bone marrow and reduce the chance of relapse. About 27 adults with acute leukemia or myelodysplastic syndrome (MDS) will receive a half-matched (haploidentical) donor transplant along with the extra radiation. The main goal is to see if more patients stay free of both the disease and serious graft-versus-host disease one year after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- targeted radiation (total marrow irradiation) plus chemotherapy (fludarabine and cyclophosphamide) followed by a half-matched stem cell transplant
- What this could lead to
- If successful, this approach could lower the chance of leukemia or MDS returning after a stem cell transplant, improving long-term survival.
- What could go wrong
- This is a small, early-phase study (27 people) and the added radiation may increase side effects like graft-versus-host disease or other toxicities. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Illinois Cancer Center
RECRUITINGChicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Frailty check may steer safer cancer care for seniors